Sensorion Appoints Amit Munshi as Chairman of the Board

Sensorion, a clinical-stage biotechnology company focused on developing therapies for hearing loss, has appointed Amit Munshi as Chairman of the Board and independent director. This change, effective April 1, 2025, follows the departure of John Furey. Munshi succeeds Khalil Barrage, who served as interim Chairman.

Munshi brings 35 years of healthcare industry experience, having led biotech firms to significant growth and exits. He was CEO of Orna Therapeutics and previously transformed Arena Therapeutics before its acquisition by Pfizer. His background includes executive roles at Amgen and founding Kythera Biopharmaceuticals.

Munshi expressed enthusiasm about joining Sensorion at a crucial phase, aiming to drive the company's innovative therapies for hearing disorders. The Board will seek shareholder ratification of Munshi’s appointment at the upcoming General Meeting.